At a glance
ClinicalIndex Comparison RecordN/AUnknown· 11,879 target
Drug / intervention
Multi-cancer early detection testdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pan-cancer Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Multi-center, Prospective Observational Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·observational·Posted Mar 30, 2021·Updated Jun 2, 2021
In Brief
An observational study evaluating Multi-cancer early detection test for Cancer. Targeting 11,879 participants across 1 site.
Detailed Summary
PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers. Blood RNA markers will also be evaluated. The study will enroll approximately 11879 participants, including participants with malignancies or benign diseases, and healthy participants.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesChina
CollaboratorsGuangzhou Burning Rock Dx Co., Ltd.
Timeline
N/AUnknownOverdue
20222023202420252026
Enrollment StartMar 2021
First PostedMar 2021
Primary CompletionMar 2023
Study CompletionJun 2023
TodayJul 2026
First PostedMar 30, 2021
Enrollment StartMar 23, 2021
Primary CompletionMar 31, 2023
Study CompletionJun 30, 2023
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 5.3 years ago
Interventions
Multi-cancer early detection testdevice
Blood collection and multi-cancer early detection test